Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

A user discusses a hair loss treatment combining minoxidil and tretinoin, noting it may enhance absorption. Some users express interest and share positive experiences, while others question its effectiveness without medical evidence.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

Genetic differences in hair follicles affect hair loss patterns. Treatments discussed include finasteride, dutasteride, minoxidil, and RU58841.

The conversation discusses the differences in inactive ingredients between Sandoz 5mg Finasteride and Proscar/Propecia, questioning the purpose of certain additives like Docusate sodium. It seeks to determine if these differences affect the effectiveness of the treatment for hair loss.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.

The conversation is about a user interested in participating in hair cloning clinical trials due to their fine hair and previous positive experience with clinical trials. They are seeking information on how to volunteer for such trials.

The conversation discusses experiences with hair loss treatments containing RootBioTec and Anagain. Users share their results and compare these treatments to Minoxidil, finasteride, and RU58841.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

2 Deoxy D Ribose may promote hair growth and aid wound healing, potentially enhancing microneedling effects. Users discuss its combination with microneedling for better hair growth results.

A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

Exosome Therapy for hair loss, including its results and cost. The discussion also touches on the various serums used in this therapy.

Amplifica raised $26 million to advance its injectable treatments for hair growth. The funding will support the clinical development of their novel therapies.

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgen receptor degraders and the need to manage drug resistance.

The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

The conversation is about a user experiencing hair thinning and considering exosome treatment after being advised against a hair transplant. The user seeks advice from others who may have tried exosomes for hair loss.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

The conversation humorously criticizes users who post hair progress photos in the wrong order. It highlights the use of treatments like Minoxidil, finasteride, and RU58841.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

The conversation discusses the benefits of combining scalp stem cell treatments and exohealer with RF microneedling before a hair transplant. The original poster recommends these treatments for better results.

The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.